FRM
GLUE icon

Fox Run Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Fox Run Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,394
Closed -$127K – 999
2025
Q1 		$127K Buy
+27,394
New +$168K 0.02% 848

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fox Run Management's GLUE Position: Q2 2025 in Review

Fox Run Management sold out of Monte Rosa Therapeutics (GLUE) in Q2 2025, closing a stake of 27,394 shares — an estimated $127K sold.

Fox Run Management first reported a position in GLUE in Q1 2025 and held it in 1 quarter. The position peaked at $127K in Q1 2025. 116 funds tracked by Wall St. Rank hold GLUE as of Q2 2025.

  • Fox Run Management reported no remaining Monte Rosa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Fox Run Management sold 27,394 Monte Rosa Therapeutics shares in Q2 2025, an estimated $127K.
  • Fox Run Management first reported a position in Monte Rosa Therapeutics in Q1 2025 and held it in 1 quarter.
  • Fox Run Management's Monte Rosa Therapeutics position peaked at $127K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.